Resource Summary Report

Generated by RRID on Aug 28, 2026

HCC1187

RRID:CVCL_1247
Type: Cell Line

Proper Citation

RRID:CVCL_1247

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1247

Proper Citation: RRID:CVCL_1247

Description: Cell line HCC1187 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: PMID:9833771, PMID:9865903, PMID:11314036, PMID:12800145, PMID:16959974, PMID:17157791, PMID:17932254, PMID:19582160, PMID:20164919, PMID:21778573, PMID:22460905, PMID:22585861, PMID:23151021, PMID:24094812, PMID:24162158, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1187

Synonyms: HCC-1187, Hamon Cancer Center 1187

Cross References: CLO:CLO_0003632, EFO:EFO_0001170, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-

3610, ArrayExpress:E-TABM-157, ATCC:CRL-2322, BioGRID_ORCS_Cell_line:874, BioSample:SAMN03471273, BioSample:SAMN10987946, cancercelllines:CVCL_1247, Cell_Model_Passport:SIDM00885, ChEMBL-Cells:CHEMBL3308845, ChEMBL-Targets:CHEMBL2366202, CLS:305781, Cosmic:749711, Cosmic:904361, Cosmic:1136366, Cosmic:1235080, Cosmic:1287916, Cosmic:1430348, Cosmic:1460231, Cosmic:1473100, Cosmic:1518110, Cosmic:1603199, Cosmic:1995422, Cosmic-CLP:749711, dbGAP:phs001839.v1.p1, DepMap:ACH-000111, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:749711, GEO:GSM185077, GEO:GSM185078, GEO:GSM186712, GEO:GSM186713, GEO:GSM217571, GEO:GSM219916, GEO:GSM344370, GEO:GSM344420, GEO:GSM350540, GEO:GSM378152, GEO:GSM783933, GEO:GSM844542, GEO:GSM847320, GEO:GSM847473, GEO:GSM887035, GEO:GSM888105, GEO:GSM1008896, GEO:GSM1053708, GEO:GSM1172956, GEO:GSM1214579, GEO:GSM1374494, GEO:GSM1374495, GEO:GSM1401672, GEO:GSM1661979, GEO:GSM1669842, IARC_TP53:21360, IARC_TP53:22810, IARC_TP53:30201, LiGeA:CCLE_850, LINCS_HMS:50578, LINCS_LDP:LCL-1324, PharmacoDB:HCC1187_469_2019, PRIDE:PXD030304, Progenetix:CVCL_1247, PubChem_Cell_line:CVCL_1247, SLKBase:3507, Wikidata:Q54881536

ID: CVCL_1247

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260815T233701+0000

Ratings and Alerts

No rating or validation information has been found for HCC1187.

No alerts have been found for HCC1187.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 121 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Esapa B, et al. (2026) An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. NPJ precision oncology, 10(1).

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Waas M, et al. (2024) Droplet-based proteomics reveals CD36 as a marker for progenitors in mammary basal epithelium. Cell reports methods, 4(4), 100741.

Roche S, et al. (2023) Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. PloS one, 18(3), e0282512.

Xie X, et al. (2023) Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. Biomedicines, 11(3).

Boyd DC, et al. (2023) Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. Cancers, 15(5).

Kj??lle S, et al. (2023) Hypoxia induced responses are reflected in the stromal proteome of breast cancer. Nature communications, 14(1), 3724.

Bhattacharya U, et al. (2023) Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers, 15(2).

Stefanski CD, et al. (2023) APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. International journal of molecular sciences, 24(8).

Hoogenboezem EN, et al. (2023) Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy. bioRxiv : the preprint server for biology.

Liu Y, et al. (2023) Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell research, 33(5), 389.

Limsakul P, et al. (2023) Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. Cancers, 15(2).

Jovanovi?? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.

Kim H, et al. (2023) Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. Cell reports, 42(10), 113256.

Hardeman AA, et al. (2022) Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. PloS one, 17(6), e0268693.

Sun Q, et al. (2022) Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1. NPJ breast cancer, 8(1), 5.

Montero JC, et al. (2022) Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. Journal of experimental & clinical cancer research : CR, 41(1), 106.

Kuhlmann L, et al. (2022) Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. Journal of proteome research, 21(9), 2224.